Table 4 |
||||||||||||||||||
|
Effect of study group on pathological attributes of interval cancers and second round screen-detected cancers |
||||||||||||||||||
|
Size (mm) |
Grade |
Node status |
Stage |
Laterality |
Tumour risk group |
|||||||||||||
|
|
|
|
|
|
|
|||||||||||||
|
20+ |
< 20 |
Odds ratioa |
3 |
1+2 |
Odds ratiob |
+ve |
-ve |
Odds ratioc |
2+ |
1 |
Odds ratiod |
Left |
Right |
Odds ratioe |
3 |
1 + 2 |
Odds ratiof |
|
|
|
||||||||||||||||||
|
Interval cancer |
||||||||||||||||||
|
Nonassessed |
160 |
124 |
1.00 |
72 |
148 |
1.00 |
101 |
133 |
1.00 |
179 |
131 |
1.00 |
139 |
162 |
1.00 |
75 |
216 |
1.00 |
|
Assessed normal |
26 |
14 |
1.44 (0.72–2.87) |
5 |
22 |
0.47 (0.17–1.28) |
13 |
18 |
0.95 (0.45–2.03) |
25 |
15 |
1.22 (0.62–2.40) |
22 |
17 |
1.51 (0.77–2.95) |
4 |
34 |
0.34 (0.12–0.99) |
|
Assessed benign |
1 |
1 |
0.78 (0.05–12.51) |
1 |
0 |
- |
1 |
2 |
0.66 (0.06–7.36) |
1 |
2 |
0.37 (0.03–4.08) |
2 |
2 |
1.17 (0.16–8.38) |
2 |
2 |
2.88 (0.40–20.81) |
|
All assessed |
27 |
15 |
1.40 (0.71–2.74) |
6 |
22 |
0.56 (0.22–1.44) |
14 |
20 |
0.92 (0.44–1.91) |
26 |
17 |
1.12 (0.58–2.15) |
24 |
19 |
1.47 (0.77–2.80) |
6 |
36 |
0.48 (0.19–1.18) |
|
Second screen cancer |
||||||||||||||||||
|
Nonassessed |
78 |
275 |
1.00 |
57 |
256 |
1.00 |
72 |
206 |
1.00 |
104 |
253 |
1.00 |
180 |
172 |
1.00 |
54 |
294 |
1.00 |
|
Assessed normal |
11 |
24 |
1.62 (0.76–3.44) |
5 |
23 |
0.98 (0.36–2.68) |
10 |
19 |
1.51 (0.67–3.39) |
13 |
22 |
1.44 (0.70–2.96) |
16 |
16 |
0.96 (0.46–1.97) |
4 |
30 |
0.73 (0.25–2.14) |
|
Assessed benign |
0 |
1 |
- |
0 |
1 |
- |
0 |
1 |
- |
0 |
1 |
- |
0 |
1 |
- |
0 |
1 |
- |
|
All assessed |
11 |
25 |
1.55 (0.73–3.29) |
5 |
24 |
0.94 (0.34–2.56) |
10 |
20 |
1.43 (0.64–3.20) |
13 |
23 |
1.37 (0.67–2.82) |
16 |
17 |
0.90 (0.44–1.84) |
4 |
31 |
0.70 (0.24–2.07) |
|
All cancers |
||||||||||||||||||
|
Nonassessed |
238 |
399 |
1.00 |
129 |
404 |
1.00 |
173 |
339 |
1.00 |
283 |
384 |
1.00 |
319 |
334 |
1.00 |
129 |
510 |
1.00 |
|
Assessed normal |
37 |
38 |
1.63 (1.01–2.64) |
10 |
45 |
0.70 (0.34–1.42) |
23 |
37 |
1.22 (0.70–2.11) |
38 |
37 |
1.39 (0.86–2.25) |
38 |
33 |
1.21 (0.74–1.97) |
8 |
64 |
0.49 (0.23–1.06) |
|
Assessed benign |
1 |
2 |
0.84 (0.08–9.29) |
1 |
2 |
1.57 (0.14–17.41) |
1 |
3 |
0.65 (0.07–6.33) |
1 |
3 |
0.45 (0.05–4.37) |
2 |
3 |
0.70 (0.12–4.21) |
2 |
3 |
2.64 (0.44–15.94) |
|
All assessed |
38 |
40 |
1.59 (0.99–2.55) |
11 |
47 |
0.73 (0.37–1.46) |
24 |
40 |
1.18 (0.69–2.01) |
39 |
40 |
1.32 (0.83–2.11) |
40 |
36 |
1.16 (0.72–1.87) |
10 |
67 |
0.59 (0.30–1.18) |
|
|
||||||||||||||||||
|
a Odds ratio of cancer measuring 20 mm and above versus < 20 mm. b Odds ratio of cancer of grade 3 versus grades 1 or 2. c Odds ratio of node positive cancer versus node negative. d Odds ratio of cancer of stage 2 or above versus stage 1. e Odds ratio of cancer in the left breast versus in the right breast. f Odds ratio of cancer of risk group 3 versus risk groups 1 or 2 [9]. |
||||||||||||||||||
|
McCann et al. Breast Cancer Res 2002 4:R11 doi:10.1186/bcr455 |
||||||||||||||||||
